Asset
MOL-4239
Moleculin Biotech Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01826201 | phase2 | completed | 2013-03-01 | 2013-08-01 | Moleculin, LLC | Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis |
| NCT04702503 | phase1 | completed | 2019-03-08 | 2019-11-15 | Moleculin Biotech, Inc. | Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) |
FDA applications (0)
This company has no applications containing this asset.